4-乙氧基3-三氟甲基苯硼酸 | 871329-83-8

• 物质功能分类: 化学试剂 - 有机试剂 - 硼酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-乙氧基3-三氟甲基苯硼酸
• 中文别名: (4-乙氧基-3-三氟甲苯基)硼酸；3-三氟甲基-4-乙氧基苯硼酸
• 英文名称: 4-ethoxy-3-(trifluoromethyl)phenylboronic acid
• 英文别名: 3-trifluoromethyl-4-ethoxyphenylboronic acid；4-Ethoxy-3-trifluoromethylphenylboronic acid；[4-ethoxy-3-(trifluoromethyl)phenyl]boronic acid
• CAS: 871329-83-8
• 化学式: C₉H₁₀BF₃O₃
• mdl: MFCD07363789
• 分子量: 233.983
• InChiKey: SHCPXHBLEGXHIV-UHFFFAOYSA-N

物化性质

• 沸点：
  333.9±52.0 °C(Predicted)
• 密度：
  1.31±0.1 g/cm3(Predicted)
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  2.61
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4-Ethoxy-3-trifluoromethylphenylboronic acid
Product Name:
Synonyms: 4-Ethoxy-3-(trifluoromethyl)phenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4-Ethoxy-3-trifluoromethylphenylboronic acid
Ingredient name:
CAS number: 871329-83-8

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H10BF3O3
Molecular weight: 234.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-amino-6-chloro-3-nitro-2-pyridinecarbonitrile 、 4-乙氧基3-三氟甲基苯硼酸 在 四(三苯基膦)钯 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 0.17h， 生成 4-amino-6-(4-ethoxy-3-trifluoromethyl-phenyl)-3-nitro-pyridine-2-carbonitrile
  参考文献：
  名称：

  6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives

  摘要：

  本发明涉及具有通式I的6-苯基-1H-咪唑[4,5-c]吡啶-4-碳腈衍生物，其中每个取代基的定义如规范和权利要求中所述，包括含有这些衍生物的药物组合物，以及利用这些衍生物制备用于治疗与cathepsin S和/或cathepsin K相关疾病的药物，如骨质疏松症、动脉粥样硬化、炎症和免疫紊乱，如类风湿性关节炎，以及慢性疼痛，如神经病理性疼痛。

  公开号：

  US20070179138A1
• 作为产物：
  描述：

  在 水 、 溶剂黄146 作用下， 以 四氢呋喃 、 hexanes 为溶剂， 生成 4-乙氧基3-三氟甲基苯硼酸
  参考文献：
  名称：

  6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives

  摘要：

  本发明涉及具有通式I的6-苯基-1H-咪唑[4,5-c]吡啶-4-碳腈衍生物，其中每个取代基的定义如规范和权利要求中所述，包括含有这些衍生物的药物组合物，以及利用这些衍生物制备用于治疗与cathepsin S和/或cathepsin K相关疾病的药物，如骨质疏松症、动脉粥样硬化、炎症和免疫紊乱，如类风湿性关节炎，以及慢性疼痛，如神经病理性疼痛。

  公开号：

  US20070179138A1

文献信息

• [EN] ARYL-HYDROXYETHYLAMINO-PYRIMIDINES AND TRIAZINES AS MODULATORS OF FATTY ACID AMIDE HYDROLASE<br/>[FR] ARYL-HYDROXYÉTHYLAMINO-PYRIMIDINES ET TRIAZINES EN TANT QUE MODULATEURS D'AMIDE D'ACIDE GRAS HYDROLASE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2009105220A1

  公开（公告）日：2009-08-27

  Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

  描述了某些芳基-羟乙基氨基嘧啶和三嗪化合物，这些化合物可用作FAAH抑制剂。这些化合物可用于制备药物组合物和治疗由脂肪酸酰胺水解酶（FAAH）活性介导的疾病状态、紊乱和症状，如焦虑、疼痛、炎症、睡眠障碍、进食障碍、能量代谢障碍和运动障碍（例如多发性硬化）。还公开了合成这些化合物的方法。
• Design of selective COX-2 inhibitors in the (aza)indazole series. Chemistry, <i>in vitro</i> studies, radiochemistry and evaluations in rats of a [¹⁸F] PET tracer
  作者：Jonathan Elie、Johnny Vercouillie、Nicolas Arlicot、Lucas Lemaire、Rudy Bidault、Sylvie Bodard、Christel Hosselet、Jean-Bernard Deloye、Sylvie Chalon、Patrick Emond、Denis Guilloteau、Frédéric Buron、Sylvain Routier

  DOI：10.1080/14756366.2018.1501043

  日期：2019.1.1

  Abstract A series of novel derivatives exhibiting high affinity and selectivity towards the COX-2 enzyme in the (aza) indazole series was developed. A short synthetic route involving a bromination/arylation sequence under microwave irradiation and direct C–H activation were established in the indazole and azaindazole series respectively. In vitro assays were conducted and structural modifications were

  抽象的 开发了在（氮杂）吲唑系列中对COX-2酶表现出高亲和力和选择性的一系列新型衍生物。分别在吲唑和氮杂吲唑系列中建立了一条简短的合成路线，涉及微波辐射下的溴化/芳基化序列和直接的C–H活化。进行了体外测定，并对这些支架进行了结构修饰，以提供具有有效COX-2抑制活性的化合物16，IC 50值为0.409 µM，相对于COX-1具有优异的选择性。释放硼酸酯后，对这种最有效的衍生物[ 18 F] 16进行了放射性标记，并在体内评估了示踪剂在神经发炎的大鼠模型中。讨论了所有化学，放射化学和生物学实验数据。
• 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
  申请人：N.V. Organon

  公开号：US07687515B2

  公开（公告）日：2010-03-30

  The present invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives having the general Formula I wherein each of the substituents is given the definition as set forth in the specification and claims, pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.

  本发明涉及具有一般式I的6-苯基-1H-咪唑[4,5-c]吡啶-4-碳腈衍生物，其中每个取代基的定义如规范和权利要求中所述，以及包含它们的制药组合物，以及利用这些衍生物制备治疗与cathepsin S和/或cathepsin K相关的疾病，如骨质疏松症、动脉粥样硬化、炎症和免疫紊乱，如类风湿性关节炎和慢性疼痛，如神经病理性疼痛的药物的用途。
• 2-Phenyl-9H-purine-6-carbonitrile derivatives as selective cathepsin S inhibitors
  作者：Jiaqiang Cai、D. Jonathan Bennett、Zoran Rankovic、Maureen Dempster、Xavier Fradera、Jonathan Gillespie、Iain Cumming、William Finlay、Mark Baugh、Sylviane Boucharens、John Bruin、Kenneth S. Cameron、William Hamilton、Jennifer Kerr、Emma Kinghorn、George McGarry、John Robinson、Paul Scullion、Joost C.M. Uitdehaag、Mario van Zeeland、Dominique Potin、Laurent Saniere、Andre Fouquet、Francois Chevallier、Hortense Deronzier、Cecile Dorleans、Eric Nicolai

  DOI：10.1016/j.bmcl.2010.06.049

  日期：2010.8

  Starting from previously disclosed equally potent cathepsin K and S inhibitor 4-propyl-6-(3-trifluoromethylphenyl) pyrimidine-2-carbonitrile 1, a novel 2-phenyl-9H-purine-6-carbonitrile scaffold was identified to provide potent and selective cathepsin S inhibitors. (C) 2010 Elsevier Ltd. All rights reserved.
• WO2007/80191
  申请人：——

  公开号：——

  公开（公告）日：——